To mark World Cholangiocarcinoma Day, we had the pleasure of speaking 🗣️ with Sydney Towle ! Sidney was diagnosed with cholangiocarcinoma and is currently undergoing treatment. 🎥 Watch her inspiring story on our Instagram account and get her perspective on the fight against cancer 👉 https://lnkd.in/eDdu2_Qb You can also find Sydney @sydneytowle on Instagram. #cancer #oncology #cholangiocarcinoma #WorldCCADay #CCA #WeAreServier #MovedByYou
Servier
Fabrication de produits pharmaceutiques
Committed to therapeutic progress to serve patient needs
À propos
Fondé pour servir la santé, Servier est un groupe pharmaceutique international gouverné par une Fondation, qui aspire à avoir un impact sociétal significatif pour les patients et pour un monde durable. Son modèle unique de gouvernance lui permet de servir pleinement sa vocation avec une vision à long terme : être engagé pour le progrès thérapeutique au bénéfice des patients. Les 21 900 collaborateurs qui composent le Groupe sont engagés autour de cette vocation commune, source d’inspiration au quotidien. Leader mondial en cardiologie, Servier a pour ambition de devenir un acteur focalisé et innovant en oncologie en ciblant des cancers difficiles à traiter. C’est pourquoi le Groupe consacre plus de 70 % de son budget de R&D au développement de thérapies ciblées et innovantes en oncologie. Les neurosciences et les maladies immuno-inflammatoires constituent un futur relais de croissance. Dans ces domaines, Servier se focalise sur un nombre restreint de pathologies spécifiques dans lesquelles une caractérisation précise des patients permet de proposer une réponse thérapeutique ciblée, grâce à la médecine de précision. Pour favoriser l’accès à des soins de qualité pour tous, et à moindre coût, le Groupe propose également une offre de médicaments génériques couvrant la majorité des pathologies, en s’appuyant sur des marques fortes en France, en Europe de l’Est, au Brésil et au Nigeria. Dans tous ces domaines, le Groupe intègre la voix du patient à chaque étape du cycle de vie du médicament. Servier, dont le siège social est basé en France, s’appuie sur une solide implantation géographique dans plus de 150 pays et a réalisé, en 2023, un chiffre d’affaires de 5,3 milliards d’euros. --- Si vous avez constaté ou si vous pensez être sujet à un problème de santé lié à l’utilisation d’un médicament Servier ou de tout autre produit de santé Servier, rendez-vous sur servier.com
- Site web
-
https://servier.com
Lien externe pour Servier
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- + de 10 000 employés
- Siège social
- Suresnes
- Type
- Société civile/Société commerciale/Autres types de sociétés
Lieux
-
Principal
Obtenir l’itinéraire
50 rue Carnot
92150 Suresnes, FR
Employés chez Servier
Nouvelles
-
🔬 Clinical trials are the cornerstone of medical innovation, yet, when it comes to rare diseases, traditional methods often pose significant challenges. 🧬 Synthetic control arms offer a transformative alternative by integrating data from external sources, such as patients who have previously participated in clinical trials or advanced statistical models. This reduces trial duration and addresses ethical concerns—especially when patient recruitment is difficult or when control arms involve forgoing treatment. 💬 Learn more from Rui(Sammi) Tang, PhD, MBA, Former Vice-President, Global Head of Biometrics at Servier, who explains how synthetic control arms can address ethical concerns, accelerate rare disease trials, and provide patients with a fairer, more inclusive approach to clinical research. Discover how this innovation is reshaping clinical trials in the latest release of #InsightsByServier 👉 https://lnkd.in/euYdnpKU #WeAreServier #InnovationInHealth
-
-
🎗️ Cholangiocarcinoma is often diagnosed too late due to a lack of information and understanding. Raising awareness of this rare cancer is more crucial than ever today! Our objective? ➡️ To encourage early diagnosis, speed up scientific advances, break patients' isolation and improve their quality of life in the face of the disease. 👇📽️ Listen to Claire Holmes, Caregiver and Patient Advocate, Steven Holmes, Cholangiocarcinoma Survivor and Patient Advocate, and Dr Angela Lamarca, Medical Oncologist specialized in Gastrointestinal Malignancies. Watch the whole interview 👉 https://lnkd.in/e2JmQh89 #cancer #oncology #cholangiocarcinoma #WorldCCADay #CCA #WeAreServier #MovedByYou
-
💡 Today is World Cholangiocarcinoma Day! This day aims to raise awareness of this devastating malignancy of the bile ducts. Cholangiocarcinoma (CCA) is often diagnosed too late due to a lack of information and understanding. Guided by patients' unmet medical needs, at Servier, we are committed to the fight against rare cancers 🎗️. Oncology is a major therapeutic priority for us, accounting for close to 70% of our R&D investment 🔬. Our objective is to offer patients a personalized and potentially more effective therapy to combat cholangiocarcinoma. To learn more about our commitments 👉 https://lnkd.in/e2JmQh89 #cancer #oncology #cholangiocarcinoma #WorldCCADay #CCA #WeAreServier #MovedByYou
-
-
🧬 Randomized trials have been the gold standard for decades, ensuring reliable data for new treatments. However, the process of conducting a trial can be challenging—particularly as regards rare diseases. 💡 One key difficulty is ensuring cohort diversity. Patient recruitment can also be slow and costly, often delaying life-saving drugs, and ethical concerns arise when using placebos in control arms. 🔬 Synthetic control arms are an innovation that allow traditional control arms to be replaced with data from external sources in some clinical trials. This external data can come from patients who have previously participated in clinical trials or from advanced statistical models. Synthetic control arms help overcome recruitment barriers, reduce trial duration and maintain scientific rigor. Explore how this breakthrough could transform clinical trials in the latest issue of #InsightsByServier 👉 https://lnkd.in/euYdnpKU #WeAreServier #InsightsByServier
Ce contenu n’est pas disponible ici
Accédez à ce contenu et plus encore dans l’application LinkedIn
-
As part of our #Servier2030 ambition, we are now focusing our R&D efforts on neurology in addition to oncology. 🧠🔬 To that end, we are targeting three families of neurological disease: refractory epilepsy, rare movement disorders, and neuromuscular diseases. In order to build a robust and promising R&D pipeline in neurology, we are dedicating significant resources and investments, particularly for the development of new drugs that slow the progression of neurological disorders or significantly alleviate their symptoms. 💊 To date, this pipeline comprises 8 research projects and 1 development project. 🚀 Learn more in the Servier 2023-2024 FY results press release 👉 https://lnkd.in/erDhvajC #ServierResults #innovation #strategy #RnD #WeAreServier #MovedByYou
-
Servier a republié ceci
This International Childhood Cancer Day (ICCD), we’re proud to champion our global awareness campaign—Cancel Child Cancer! In partnership with Servier, we’re working to close the gap in childhood cancer care—because no child’s survival should depend on where they live. In high-income countries like the U.S., over 80% of children survive cancer. But in low- and middle-income countries, that rate drops to just 20-30%—an unacceptable disparity. This February, join us in honoring ICCD and the ‘Learn, Heal, Thrive’ campaign. Your support helps children: 📚 Learn in hospital school programs 🩺 Heal with tailored medical care 💛 Thrive with emotional support Together, we can shape the future of childhood cancer care. ❤️ Take action today — donate now: https://lnkd.in/gtP5BkXR #CancelChildCancer #ICCD2025 #EqualAccessToCare #ChildhoodCancerAwareness #InspiringAction
-
-
🌍 Every year, 400,000 children are diagnosed with cancer worldwide, but survival rates vary drastically between high- and low-income countries. In high-income countries, survival rates exceed 80%, while in low-income countries this figure can fall below 30%. This disparity is driven by factors such as limited awareness among healthcare professionals, a lack of access to treatment and under-resourced healthcare infrastructure. 🎗️ Led by Divya S., World Child Cancer USA is working relentlessly to close this survival gap. Its approach includes: 📌 Focusing on early diagnosis 📌 Providing financial and emotional support to families 📌 Improving the quality of care for children in underserved regions 💡 The organization's initiatives, such as training healthcare professionals and supporting families, are key to addressing the root causes of these survival disparities. 🌟 World Child Cancer USA is making a significant difference in the lives of children and families affected by cancer worldwide. Learn more about its work and how you can support the cause. Discover how World Child Cancer USA is closing the survival gap in pediatric cancer care in our latest #InsightsByServier article 👉 https://bit.ly/3QhKWxi #WorldChildCancer #HealthEquity #ChildhoodCancer
-
The 2023-2024 FY results confirm our global leadership position in cardio-metabolic and venous diseases. 🌍 We are the No. 1 leading pharmaceutical group in hypertension and No. 5 in cardiology worldwide. In line with our #Servier2030 ambition, we intend to leverage all drivers needed to improve patient adherence to treatment. We develop incremental innovations (Single Pill Combinations) 💊 as well as innovative digital services that aim to improve diagnosis, knowledge of chronic diseases, and therapeutic compliance. 📲🩺 Learn more in the Servier 2023-2024 FY results press release 👉 https://lnkd.in/erDhvajC #ServierResults #innovation #strategy #RnD #WeAreServier #MovedByYou
-
Servier a republié ceci
🌟We’re excited to announce Manette le Grange as a speaker at the Second Global OncoThon, happening on February 15, 2025 – Childhood Cancer Awareness Day! On this important day, Manette Le Grange joins global experts, advocates, and innovators to drive impactful discussions and collaboration in the fight against childhood and all cancers. 📅Date: February 15, 2025 – Childhood Cancer Awareness Day 📍Where: On OncoDaily TV Be part of this global movement shaping the future of cancer care. International Society of Paediatric Oncology - SIOP Servier #OncoDaily #OncoThon #SIOP #PedOnc #ChildhoodCancerAwarenessDay #CancerResearch #Fundraising #Oncology #Cancer
-